Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Date:5/6/2008

candidates may have unanticipated adverse side effects or inadequate therapeutic efficacy; Cadence may experience delays and increased costs with respect to completion of pre-commercialization manufacturing development activities, and may be required to perform additional pre-clinical or clinical testing as a result of changes to manufacturing processes for its product candidates; the company may require substantial additional funding to complete its clinical development programs and successfully launch its products, and it may not be able to raise sufficient capital when needed, or at all; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue

SVP & Chief Financial Officer

Cadence Pharmaceuticals, Inc.

858-436-1400

Anna Gralinska

Director, Investor Relations

Cadence Pharmaceuticals, Inc.

858-436-1452

CADENCE PHARMACEUTICALS, INC.

(a development stage company)

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)

Three Months Ended

March
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
7. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
8. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
9. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
11. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- AVT, Inc. (OTC Markets: AVTC) ( www.autoretail.com ), a ... announced today that they are starting production of the ... is designed for placement inside optical shops and Eye ... there are over 20,000 optical stores in America.  ... first automated kiosk dedicated to cleaning and sanitizing eyeglasses ...
(Date:9/22/2014)... 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) ... 2014 ended July 31, 2014 on Monday, September 29 before ... the results at 11:00 AM ET. Participating in the call ... A. Krakauer , President and CEO; Jorgen B. Hansen ... , Senior Vice President, CFO and Treasurer; and Seth ...
(Date:9/22/2014)... Pa. , Sept. 22, 2014  Inovio ... today it has initiated a phase I clinical ... will evaluate the safety, tolerability, and immunogenicity of ... (HPV-6), which causes most aerodigestive cancers. ... throat, vocal cords, and parts of the esophagus ...
Breaking Medicine Technology:Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
(Date:9/22/2014)... (September 22, 2014) McMaster scientists have found that ... class of antibiotics. , Although dozens of antibiotics ... how a certain part of bacteria are created, and ... , The discovery is important as there is ... the cures for infections ineffective. The World Health Organization ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 This Flash ... on stakeholder management needs for the Prostate Cancer market. ... Experts on stakeholder strategies for any launching Prostate Cancer ... of differentiation within an increasingly crowded market , ... The impact of identifying community-based thought leaders and stakeholders ...
(Date:9/22/2014)... researchers have published a pilot study showing the ... people with multiple sclerosis (MS). Improvements were ... and pain. "Development and effectiveness of a ... Description and outcomes" was epublished ahead of print ... of MS Care (doi: 10.7224/1537-2073.2013-045). The authors ...
(Date:9/22/2014)... New York, New York (PRWEB) September 22, 2014 ... risks associated with the use of power morcellators ... Liebhard LLP notes a new report detailing the ... despite warnings from federal regulators that specifically discouraged ... these physicians believe that the potential cancer risks ...
(Date:9/22/2014)... Bronson Gray HealthDay Reporter ... pregnant woman wonders: What can I do to help ensure ... supplements as prescribed may play a role in reducing the ... The researchers found that mothers of children with autism ... and during pregnancy than those whose children seem to be ...
Breaking Medicine News(10 mins):Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3
... , , , ... Carefx Corporation , a leading provider of interoperable workflow solutions ... one of its clients, the Louisiana Rural Health Information Exchange (LARHIX), was ... Information Executives , a top healthcare information technology magazine. , ...
... , , LAKE ... ), a leading global specialty pharmaceutical and medication delivery company, today ... sales for the quarter were $957 million, and adjusted* diluted earnings ... described later in this press release and the attached schedules.) , ...
... , PITTSBURGH, July 29 Mylan Inc. ... its executive management team. The changes, which reflect internal promotions and ... , Heather Bresch has been promoted to president. ... leadership responsibilities related to the day-to-day operations of the company. She ...
... , , , ... WPI ), a leader in generic and specialty branded pharmaceuticals, today ... Excluding special items as detailed in the reconciliation table below, adjusted ... per diluted share, an increase of $15.8 million or 29 percent. ...
... , , SAFETY ... Prevention Specialist, like many, did not start out with a drug-free ... fought his own battle with substance abuse that ended with his ... , After successfully completing treatment at Narconon, John decided ...
... ... are delighted to announce their partnership to better meet the needs of the autism community in ... ... and AutismOne are delighted to announce their partnership to better meet the needs of ...
Cached Medicine News:Health News:Top Healthcare Magazine Awards Carefx Client '2009 IT Project of the Year' 2Health News:Top Healthcare Magazine Awards Carefx Client '2009 IT Project of the Year' 3Health News:Hospira Reports Second-Quarter 2009 Results 2Health News:Hospira Reports Second-Quarter 2009 Results 3Health News:Hospira Reports Second-Quarter 2009 Results 4Health News:Hospira Reports Second-Quarter 2009 Results 5Health News:Hospira Reports Second-Quarter 2009 Results 6Health News:Hospira Reports Second-Quarter 2009 Results 7Health News:Hospira Reports Second-Quarter 2009 Results 8Health News:Hospira Reports Second-Quarter 2009 Results 9Health News:Hospira Reports Second-Quarter 2009 Results 10Health News:Hospira Reports Second-Quarter 2009 Results 11Health News:Hospira Reports Second-Quarter 2009 Results 12Health News:Hospira Reports Second-Quarter 2009 Results 13Health News:Hospira Reports Second-Quarter 2009 Results 14Health News:Hospira Reports Second-Quarter 2009 Results 15Health News:Hospira Reports Second-Quarter 2009 Results 16Health News:Hospira Reports Second-Quarter 2009 Results 17Health News:Hospira Reports Second-Quarter 2009 Results 18Health News:Hospira Reports Second-Quarter 2009 Results 19Health News:Hospira Reports Second-Quarter 2009 Results 20Health News:Hospira Reports Second-Quarter 2009 Results 21Health News:Hospira Reports Second-Quarter 2009 Results 22Health News:Hospira Reports Second-Quarter 2009 Results 23Health News:Hospira Reports Second-Quarter 2009 Results 24Health News:Hospira Reports Second-Quarter 2009 Results 25Health News:Hospira Reports Second-Quarter 2009 Results 26Health News:Hospira Reports Second-Quarter 2009 Results 27Health News:Hospira Reports Second-Quarter 2009 Results 28Health News:Mylan Announces Enhancements to Executive Management Team 2Health News:Mylan Announces Enhancements to Executive Management Team 3Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 2Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 3Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 4Health News:Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook 5
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Inquire...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: